Pulmonary Embolism Treatments

Find Pulmonary Embolism Treatments

Generic Name

Dabigatran Etexilate

Brand Names

Dabigatran, Pradaxa

FDA approval date: August 08, 2011

Classification: Direct Thrombin Inhibitor

Form: Pellet, Capsule

What is Dabigatran (Dabigatran Etexilate)?

Dabigatran etexilate capsules are a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation.

Approved To Treat

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

The DISTINCT Trial: inDividual, Targeted thrombosIS Prophylaxis Versus the Standard 'One Size Fits All' Approach in Patients Undergoing Total hIp or Total kNee replaCemenT: a National, Multicenter, Randomized, Multi-arm, Open-label Trial.

Enrollment Status: Recruiting

Publish Date: September 08, 2026

Intervention Type: Other

Study Phase: Phase 4

Summary: After hip or knee replacement all patients receive a standardized treatment with blood thinners, this medication is called thrombosis prophylaxis. However, despite this standard treatment some individuals still develop venous thrombosis (VTE), while others experience bleeding. This indicates that not all patients have the same VTE risk following surgery. Individualizing the amount of thrombosis pr...

SAfety and eFfectiveness of cathetER Ablation for Atrial Fibrillation With Intracranial Hemorrhage (SAFER-AF)

Enrollment Status: Recruiting

Publish Date: August 07, 2026

Intervention Type: Procedure, Drug

Study Phase: Not Applicable

Summary: SAFER-AF is an investigator-initiated, multicenter, open-label, parallel-group trial comparing catheter ablation versus usual care in patients with atrial fibrillation and intracranial hemorrhage.

Direct Oral Anticoagulant Levels in Chinese Patients With Atrial Fibrillation - A Real- World Pharmacokinetic Study

Enrollment Status: Recruiting

Publish Date: July 30, 2026

Intervention Type: Diagnostic test

Summary: Direct oral anticoagulants (DOACs) have emerged as safe and efficacious ischemic stroke prophylaxis for non-valvular atrial fibrillation (NVAF). All four DOACs - apixaban, dabigatran, edoxaban, and rivaroxaban - were shown to reduce the risk of major bleeding compared to warfarin. The predictable pharmacokinetic profiles of DOACs also favour their use over warfarin. Together with increasing AF inc...

View All Clinical Trials